GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Simrat Sohal, Compliance Officer and Senior Management Personnel (SMP) of GlaxoSmithKline Pharmaceuticals Limited, has resigned effective close of business hours on 5th August 2026. The reason stated is to pursue opportunities outside the Company. The resignation was communicated on 19th May 2026, and the Company confirmed alignment with the proposed final working date. No replacement has been announced in this filing, and the Company is expected to initiate a transition process.
The departure of a Compliance Officer is a routine but notable KMP-level change. Investors should monitor for the appointment of a successor to ensure regulatory compliance functions remain uninterrupted.